Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma

NCT06909877 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)

Interventions

DRUG: HH2853 Tablets

Sponsor

Haihe Biopharma Co., Ltd.